BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22834909)

  • 1. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
    Eifler JB; Feng Z; Lin BM; Partin MT; Humphreys EB; Han M; Epstein JI; Walsh PC; Trock BJ; Partin AW
    BJU Int; 2013 Jan; 111(1):22-9. PubMed ID: 22834909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
    Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
    Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
    Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
    Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
    Huang Y; Isharwal S; Haese A; Chun FK; Makarov DV; Feng Z; Han M; Humphreys E; Epstein JI; Partin AW; Veltri RW
    BJU Int; 2011 May; 107(10):1562-9. PubMed ID: 20875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
    JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-Stop-Shop Whole-Body
    Thalgott M; Düwel C; Rauscher I; Heck MM; Haller B; Gafita A; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy.
    Gupta RT; Faridi KF; Singh AA; Passoni NM; Garcia-Reyes K; Madden JF; Polascik TJ
    Urol Oncol; 2014 Nov; 32(8):1292-9. PubMed ID: 24863013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
    Gupta RT; Brown AF; Silverman RK; Tay KJ; Madden JF; George DJ; Polascik TJ
    AJR Am J Roentgenol; 2016 Jul; 207(1):87-95. PubMed ID: 27064383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yonsei nomogram to predict lymph node invasion in Asian men with prostate cancer during robotic era.
    Kim KH; Lim SK; Kim HY; Han WK; Choi YD; Chung BH; Hong SJ; Rha KH
    BJU Int; 2014 Apr; 113(4):598-604. PubMed ID: 24006951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
    Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
    J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
    Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
    Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
    Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
    Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for pelvic lymphadenectomy in prostate cancer.
    Link RE; Morton RA
    Urol Clin North Am; 2001 Aug; 28(3):491-8. PubMed ID: 11590808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the partin nomogram for prostate cancer in a national sample.
    Yu JB; Makarov DV; Sharma R; Peschel RE; Partin AW; Gross CP
    J Urol; 2010 Jan; 183(1):105-11. PubMed ID: 19913246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis.
    Egan AJ; Bostwick DG
    Am J Surg Pathol; 1997 Dec; 21(12):1496-500. PubMed ID: 9414194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.